Zealand Pharma drops as dasiglucagon study misses primary endpoint

 

• Zealand Pharma (NASDAQ:ZEAL) down 10% in premarket in reaction to topline data from first Phase 3 trial evaluating dasiglucagon as a treatment of Congenital Hyperinsulinism (CHI), a rare disease in which infants are born with life threatening hypoglycemia (low blood glucose) due to excess insulin secretion.
• The trial showed that dasiglucagon on top of standard of care didn’t significantly reduce rate of hypoglycemia compared to SOC alone when assessed by intermittent self-measured plasma glucose, the primary endpoint of the trial.
• However, hypoglycemia was reduced by 40–50% with dasiglucagon as compared to SOC alone when assessed by blinded continuous glucose monitoring (exploratory analysis)
• Company to engage with regulatory authorities to discuss the results while awaiting the outcome of the second phase 3-trial in younger children with CHI.
• https://seekingalpha.com/news/3644441-zealand-pharma-drops-dasiglucagon-study-fails-to-meet-primary-endpoint